Wilson Disease

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 1221-1238

  Roberts, Eve A ^a   Cox, Diane W ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37049038376     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50071-1     Document Type: Chapter

References (200)

1. Wilson SAK Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912, 34:295-507.
2. Scheinberg IH, Gitlin D Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease). Science 1952, 116:484-485.
3. Walshe JM Wilson's disease. New oral therapy. Lancet 1956, i:25-26.
4. Bearn AG A genetical analysis of thirty families with Wilson's disease (hepatolenticular degeneration). Ann Hum Genet 1960, 24:33-43.
5. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993, 5:327-337.
6. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993, 5:344-350.
7. Petrukhin K, Fischer SG, Pirastu M, et al. Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 1993, 5:338-343.
8. DiDonato M, Narindrasorasak S, Forbes JR, et al. Expression, purification, and metal binding properties of the N-terminal domain from the Wilson disease putative copper-transporting ATPase (ATP7B). J Biol Chem 1997, 272:33279-33282.
9. Fatemi N, Sarkar B. Structural and functional insights of Wilson disease copper-transporting ATPase. J Bioenerg Biomembr 2002, 34:339-349.
10. Trumbo P, Yates AA, Schlicker S, Poos M Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc 2001, 101:294-301.
11. Sharp PA Ctr1 and its role in body copper homeostasis. Int J Biochem Cell Biol 2003, 35:288-291.
12. Frydman M, Bonne-Tamir B, Farrer LA, et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci USA 1985, 82:1819-1821.
13. Efremov RG, Kosinsky YA, Nolde DE, et al. Molecular modelling of the nucleotide-binding domain of Wilson's disease protein: location of the ATP-binding site, domain dynamics and potential effects of the major disease mutations. Biochem J 2004, 382:293-305.
14. DiDonato M, Hsu HF, Narindrasorasak S, et al. Copper-induced conformational changes in the N-terminal domain of the Wilson disease copper-transporting ATPase. Biochemistry 2000, 39:1890-1896.
15. Klomp AE, Juijn JA, van der Gun LT, et al. The N-terminus of the human copper transporter 1 (hCTR1) is localized extracellularly, and interacts with itself. Biochem J 2003, 370:881-889.
16. Guo Y, Smith K, Lee J, et al. Identification of methionine-rich clusters that regulate copper-stimulated endocytosis of the human Ctr1 copper transporter. J Biol Chem 2004, 279:17428-17433.
17. Lee J, Petris MJ, Thiele DJ Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem 2002, 277:40253-40259.
18. Field LS, Luk E, Culotta VC Copper chaperones: personal escorts for metal ions. J Bioenerg Biomembr 2002, 34:373-379.
19. Amaravadi R, Glerum DM, Tzagoloff A Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum Genet 1997, 99:329-333.
20. Horng YC, Cobine PA, Maxfield AB, et al. Specific copper transfer from the Cox17 metallochaperone to both Sco1 and Cox11 in the assembly of yeast cytochrome C oxidase. J Biol Chem 2004, 279:35334-35340.
21. Larin D, Mekios C, Das K, et al. Characterization of the interaction between the Wilson and Menkes disease proteins and the cytoplasmic copper chaperone, HAH1p. J Biol Chem 1999, 274:28497-28504.
22. Hamza I, Schaefer M, Klomp LW, Gitlin JD Interaction of the copper chaperone HAH1 with the Wilson disease protein is essential for copper homeostasis. Proc Natl Acad Sci USA 1999, 96:13363-13368.
23. Nagano K, Nakamura K, Urakami KI, et al. Intracellular distribution of the Wilson's disease gene product (ATPase7B) after in vitro and in vivo exogenous expression in hepatocytes from the LEC rat, an animal model of Wilson's disease. Hepatology 1998, 27:799-807.
24. Schaefer M, Roelofsen H, Wolters H, et al. Localization of the Wilson's disease protein in human liver. Gastroenterology 1999, 117:1380-1385.
25. Harada M, Kumemura H, Sakisaka S, et al. Wilson disease protein ATP7B is localized in the late endosomes in a polarized human hepatocyte cell line. Int J Mol Med 2003, 11:293-298.
26. Cater MA, Forbes J, La Fontaine S, et al. Intracellular trafficking of the human Wilson protein: the role of the six N-terminal metal-binding sites. Biochem J 2004, 380:805-813.
27. van De Sluis B, Rothuizen J, Pearson PL, et al. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. Hum Mol Genet 2002, 11:165-173.
28. Coronado VA, Damaraju D, Kohijoki R, Cox DW New haplotypes in the Bedlington terrier indicate complexity in copper toxicosis. Mamm Genome 2003, 14:483-491.
29. Hyun C, Lavulo LT, Filippich LJ Evaluation of haplotypes associated with copper toxicosis in Bedlington terriers in Australia. Am J Vet Res 2004, 65:1573-1579.
30. Tao TY, Liu F, Klomp L, et al. The copper toxicosis gene product MURR1 directly interacts with the Wilson disease protein. J Biol Chem 2003, 278:41593-41596.
31. Biasio W, Chang T, McIntosh CJ, McDonald FJ Identification of MURR1 as a regulator of the human delta epithelial sodium channel. J Biol Chem 2004, 279:5429-5434.
32. Burstein E, Ganesh L, Dick RD, et al. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J 2004, 23:244-254.
33. Burstein E, Hoberg JE, Wilkinson AS, et al. COMMD proteins: a novel family of structural and functional homologs of MURR1. J Biol Chem 2005, 280:22222-22232.
34. Safaei R, Howell SB Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005, 53:13-23.
35. Dufner-Beattie J, Langmade SJ, Wang F, et al. Structure, function, and regulation of a subfamily of mouse zinc transporter genes. J Biol Chem 2003, 278:50142-50150.
36. Eide DJ The SLC39 family of metal ion transporters. Pflugers Arch 2004, 447:796-800.
37. Sokol RJ, Twedt D, McKim JM, et al. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology 1994, 107:1788-1798.
38. Pena MM, Lee J, Thiele DJ A delicate balance: homeostatic control of copper uptake and distribution. J Nutr 1999, 129:1251-1260.
39. Deng DX, Ono S, Koropatnick J, Cherian MG Metallothionein and apoptosis in the toxic milk mutant mouse. Lab Invest 1998, 78:175-183.
40. Oikawa S, Kawanishi S. Site-specific DNA damage induced by NADH in the presence of copper(II): role of active oxygen species. Biochemistry 1996, 35:4584-4590.
41. Yamamoto H, Hirose K, Hayasaki Y, et al. Mechanism of enhanced lipid peroxidation in the liver of Long-Evans cinnamon (LEC) rats. Arch Toxicol 1999, 73:457-464.
42. 2+. Toxicology 2000, 143:263-273.
43. Aston NS, Watt N, Morton IE, et al. Copper toxicity affects proliferation and viability of human hepatoma cells (HepG2 line). Hum Exp Toxicol 2000, 19:367-376.
44. Seth R, Yang S, Choi S, et al. In vitro assessment of copper-induced toxicity in the human hepatoma line, Hep G2. Toxicol In Vitro 2004, 18:501-509.
45. Barnham KJ, McKinstry WJ, Multhaup G, et al. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 2003, 278:17401-17407.
46. Mansouri A, Gaou I, Fromenty B, et al. Premature oxidative aging of hepatic mitochondrial DNA in Wilson's disease. Gastroenterology 1997, 113:599-605.
47. von Herbay A, de Groot H, Hegi U, et al. Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. J Hepatol 1994, 20:41-46.
48. Ogihara H, Ogihara T, Miki M, et al. Plasma copper and antioxidant status in Wilson's disease. Pediatr Res 1995, 37:219-226.
49. Hussain SP, Raja K, Amstad PA, et al. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci USA 2000, 97:12770-12775.
50. Roberts EA, Schilsky ML A practice guideline on Wilson disease. Hepatology 2003, 37:1475-1492.
51. Wilson DC, Phillips MJ, Cox DW, Roberts EA Severe hepatic Wilson's disease in preschool-aged children. J Pediatr 2000, 137:719-722.
52. Gow PJ, Smallwood RA, Angus PW, et al. Diagnosis of Wilson's disease: an experience over three decades. Gut 2000, 46:415-419.
53. Danks DM, Metz G, Sewell R, Prewett EJ Wilson's disease in adults with cirrhosis but no neurological abnormalities. Br Med J 1990, 301:331-332.
54. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005, 41:668-670.
55. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003, 23:139-142.
56. Ahmed A, Feller ER Rupture of the spleen as the initial manifestation of Wilson's disease. Am J Gastroenterol 1996, 91:1454-1455.
57. Scott J, Gollan JL, Samourian S, Sherlock S Wilson's disease, presenting as chronic active hepatitis. Gastroenterology 1978, 74:645-651.
58. Schilsky ML, Scheinberg IH, Sternlieb I Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 1991, 100:762-767.
59. Milkiewicz P, Saksena S, Hubscher SG, Elias E Wilson's disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol 2000, 15:570-574.
60. Walshe JM, Waldenstrom E, Sams V, et al. Abdominal malignancies in patients with Wilson's disease. Q J Med 2003, 96:657-662.
61. Iwadate H, Ohira H, Suzuki T, et al. Hepatocellular carcinoma associated with Wilson's disease. Intern Med 2004, 43:1042-1045.
62. Prashanth LK, Taly AB, Sinha S, et al. Wilson's disease: diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry 2004, 75:907-909.
63. Carlson MD, Al-Mateen M, Brewer GJ Atypical childhood Wilson's disease. Pediatr Neurol 2004, 30:57-60.
64. Ferenci P. Review article: diagnosis and current therapy of Wilson's disease. Aliment Pharmacol Ther 2004, 19:157-165.
65. Oder W, Prayer L, Grimm G, et al. Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993, 43:120-124.
66. Brewer GJ Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 2005, 19:185-192.
67. Oder W, Grimm G, Kollegger H, et al. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J Neurol 1991, 238:281-287.
68. Dening TR The neuropsychiatry of Wilson's disease: a review. Int J Psychiatry Med 1991, 21:135-148.
69. Rathbun JK Neuropsychological aspects of Wilson's disease. Int J Neurosci 1996, 85:221-229.
70. Azizi E, Eshel G, Aladjem M. Hypercalciuria and nephrolithiasis as a presenting sign in Wilson disease. Eur J Pediatr 1989, 148:548-549.
71. Golding DN, Walshe JM Arthropathy of Wilson's disease. Study of clinical and radiological features in 32 patients. Ann Rheum Dis 1977, 36:99-111.
72. Factor SM, Cho S, Sternlieb I, et al. The cardiomyopathy of Wilson's disease. Myocardial alterations in nine cases. Virchows Arch [Pathol Anat] 1982, 397:301-311.
73. Hlubocka Z, Maracek Z, Linhart A, et al. Cardiac involvement in Wilson disease. J Inher Metab Dis 2002, 25:269-277.
74. Weizman Z, Picard E, Barki Y, Moses S. Wilson's disease associated with pancreatitis. J Pediatr Gastroenterol Nutr 1988, 7:931-933.
75. Carpenter TO, Carnes DL, Anast CS Hypoparathyroidism in Wilson's disease. N Engl J Med 1983, 309:873-877.
76. Kaushansky A, Frydman M, Kaufman H, Homburg R. Endocrine studies of the ovulatory disturbances in Wilson's disease (hepatolenticular degeneration). Fertil Steril 1987, 47:270-273.
77. Tarnacka B, Rodo M, Cichy S, Czlonkowska A. Procreation ability in Wilson's disease. Acta Neurol Scand 2000, 101:395-398.
78. Gaffney D, Fell GS, O'Reilly DS. ACP best practice no 163. Wilson's disease: acute and presymptomatic laboratory diagnosis and monitoring. J Clin Pathol 2000, 53:807-812.
79. Steindl P, Ferenci P, Dienes HP, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997, 113:212-218.
80. Sanchez-Albisua I, Garde T, Hierro L, et al. A high index of suspicion: the key to an early diagnosis of Wilson's disease in childhood. J Pediatr Gastroenterol Nutr 1999, 28:186-190.
81. Walshe JM Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003, 40:115-121.
82. Macintyre G, Gutfreund KS, Martin WR, et al. Value of an enzymatic assay for the determination of serum ceruloplasmin. J Lab Clin Med 2004, 144:294-301.
83. Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995, 92:2539-2543.
84. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003, 23:345-350.
85. Harris ZL, Durley AP, Man TK, Gitlin JD Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999, 96:10812-10817.
86. Luca P, Demelia L, Lecca S, et al. Massive hepatic haemosiderosis in Wilson's disease. Histopathology 2000, 37:187-189.
87. Shiono Y, Wakusawa S, Hayashi H, et al. Iron accumulation in the liver of male patients with Wilson disease. Am J Gastroenterol 2001, 96:3147-3151.
88. Garcia-Villarreal L, Daniels S, Shaw SH, et al. High prevalence of the very rare Wilson disease gene mutation Leu708Pro in the island of Gran Canaria (Canary Islands, Spain): a genetic and clinical study. Hepatology 2000, 32:1329-1336.
89. Martins da Costa C, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 1992, 15:609-615.
90. Nuttall KL, Palaty J, Lockitch G Reference limits for copper and iron in liver biopsies. Ann Clin Lab Sci 2003, 33:443-450.
91. Faa G, Nurchi V, Demelia L, et al. Uneven hepatic copper distribution in Wilson's disease. J Hepatol 1995, 22:303-308.
92. Song YM, Chen MD A single determination of liver copper concentration may misdiagnose Wilson's disease. Clin Biochem 2000, 33:589-590.
93. 65Cu) in the differential diagnosis of Wilson's disease. Clin Sci (Colch) 1995, 88:727-732.
94. Saatci I, Topcu M, Baltaoglu FF, et al. Cranial MR findings in Wilson's disease. Acta Radiol 1997, 38:250-258.
95. Alanen A, Komu M, Penttinen M, Leino R. Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease. Br J Radiol 1999, 72:749-756.
96. Kozic D, Svetel M, Petrovic B, et al. MR imaging of the brain in patients with hepatic form of Wilson's disease. Eur J Neurol 2003, 10:587-592.
97. Stromeyer FW, Ishak KG Histology of the liver in Wilson's disease: a study of 34 cases. Am J Clin Pathol 1980, 73:12-24.
98. Ludwig J, Moyer TP, Rakela J The liver biopsy diagnosis of Wilson's disease. Methods in pathology. Am J Clin Pathol 1994, 102:443-446.
99. Sternlieb I. Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology 1968, 55:354-367.
100. Weirich G, Cabras AD, Serra S, et al. Rapid identification of Wilson's disease carriers by denaturing high-performance liquid chromatography. Prev Med 2002, 35:278-284.
101. Thomas GR, Forbes JR, Roberts EA, et al. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995, 9:210-217.
102. Loudianos G, Dessi V, Lovicu M, et al. Mutation analysis in patients of Mediterranean descent with Wilson disease: identification of 19 novel mutations. J Med Genet 1999, 36:833-836.
103. Waldenstrom E, Lagerkvist A, Dahlman T, et al. Efficient detection of mutations in Wilson disease by manifold sequencing. Genomics 1996, 37:303-309.
104. Caca K, Ferenci P, Kuhn HJ, et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol 2001, 35:575-581.
105. Gu YH, Kodama H, Du SL, et al. Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease. Clin Genet 2003, 64:479-484.
106. Loudianos G, Dessi V, Lovicu M, et al. Molecular characterization of Wilson disease in the Sardinian population - evidence of a founder effect. Hum Mutat 1999, 14:294-303.
107. Cullen LM, Prat L, Cox DW Genetic variation in the promoter and 5' UTR of the copper transporter, ATP7B, in patients with Wilson disease. Clin Genet 2003, 64:429-432.
108. Lovicu M, Dessi V, Zappu A, et al. Efficient strategy for molecular diagnosis of Wilson disease in the Sardinian population. Clin Chem 2003, 49:496-498.
109. Huster D, Weizenegger M, Kress S, et al. Rapid detection of mutations in Wilson disease gene ATP7B by DNA strip technology. Clin Chem Lab Med 2004, 42:507-510.
110. Thomas GR, Jensson O, Gudmundsson G, et al. Wilson disease in Iceland: a clinical and genetic study. Am J Hum Genet 1995, 56:1140-1146.
111. Kim EK, Yoo OJ, Song KY, et al. Identification of three novel mutations and a high frequency of the Arg778Leu mutation in Korean patients with Wilson disease. Hum Mutat 1998, 11:275-278.
112. Nanji MS, Nguyen VT, Kawasoe JH, et al. Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 1997, 60:1423-1429.
113. Deguti MM, Genschel J, Cancado EL, et al. Wilson disease: novel mutations in the ATP7B gene and clinical correlation in Brazilian patients. Hum Mutat 2004, 23:398.
114. Hsi G, Cox DW A comparison of the mutation spectra of Menkes disease and Wilson disease. Hum Genet 2004, 114:165-172.
115. Forbes JR, Cox DW Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant?. Am J Hum Genet 1998, 63:1663-1674.
116. Huster D, Hoppert M, Lutsenko S, et al. Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology 2003, 124:335-345.
117. Payne AS, Kelly EJ, Gitlin JD Functional expression of the Wilson disease protein reveals mislocalization and impaired copper-dependent trafficking of the common H1069Q mutation. Proc Natl Acad Sci USA 1998, 95:10854-10859.
118. Forbes JR, Cox DW Copper-dependent trafficking of Wilson disease mutant ATP7B proteins. Hum Mol Genet 2000, 9:1927-1935.
119. Panagiotakaki E, Tzetis M, Manolaki N, et al. Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A 2004, 131A:168-173.
120. Stapelbroek JM, Bollen CW, van Amstel JK, et al. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol 2004, 41:758-763.
121. Coronado VA, Bonneville JA, Nazer H, et al. COMMDI (MURR1) as a candidate in patients with copper storage disease of undefined etiology. 2005, submitted.
122. Stuehler B, Reichert J, Stremmel W, Schaefer M. Analysis of the human homologue of the canine copper toxicosis gene MURR1 in Wilson disease patients. J Mol Med 2004, 82:629-634.
123. Klein D, Lichtmannegger J, Heinzmann U, Summer KH Dissolution of copper-rich granules in hepatic lysosomes by D-penicillamine prevents the development of fulminant hepatitis in Long-Evans cinnamon rats. J Hepatol 2000, 32:193-201.
124. Sarkar B. Treatment of Wilson and Menkes diseases. Chem Rev 1999, 99:2535-2544.
125. Brewer GJ, Terry CA, Aisen AM, Hill GM Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987, 44:490-493.
126. Huang CC, Chu NS Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. Eur Neurol 1998, 39:32-37.
127. Huang CC, Chu NS Wilson's disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol Scand 1996, 93:215-218.
128. Walshe JM Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients. Q J Med 1989, 70:253-263.
129. Deutscher J, Kiess W, Scheerschmidt G, Willgerodt H. Potential hepatotoxicity of penicillamine treatment in three patients with Wilson's disease. J Pediatr Gastroenterol Nutr 1999, 29:628.
130. Coatesworth AP, Darnton SJ, Green RM, et al. A case of systemic pseudo-pseudoxanthoma elasticum with diverse symptomatology caused by long-term penicillamine use. J Clin Pathol 1998, 51:169-171.
131. Amichai B, Rotem A, Metzker A. D-penicillamine-induced elastosis perforans serpiginosa and localized cutis laxa in a patient with Wilson's disease. Isr J Med Sci 1994, 30:667-669.
132. Siegemund R, Lossner J, Gunther K, et al. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease. Acta Neurol Scand 1991, 83:364-366.
133. Walshe JM Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982, 1:643-647.
134. Scheinberg IH, Jaffe ME, Sternlieb I The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 1987, 317:209-213.
135. Dahlman T, Hartvig P, Lofholm M, et al. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine). Q J Med 1995, 88:609-616.
136. Dubois RS, Rodgerson DO, Hambidge KM Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine). J Pediatr Gastroenterol Nutr 1990, 10:77-81.
137. Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003, 60:379-385.
138. Ogra Y, Suzuki KT Targeting of tetrathiomolybdate on the copper accumulating in the liver of LEC rats. J Inorg Biochem 1998, 70:49-55.
139. Karunajeewa H, Wall A, Metz J, Grigg A. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust NZ J Med 1998, 28:215-216.
140. Brewer GJ Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 2003, 7:11-20.
141. Hoogenraad TU, Van Hattum J, Van den Hamer CJ Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987, 77:137-146.
142. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, et al. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992, 120:380-386.
143. Lee DY, Brewer GJ, Wang YX Treatment of Wilson's disease with zinc. VII. Protection of the liver from copper toxicity by zinc-induced metallothionein in a rat model. J Lab Clin Med 1989, 114:639-645.
144. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med 1998, 132:264-278.
145. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V. Treatment of Wilson's disease with zinc. IX: response of serum lipids. J Lab Clin Med 1991, 118:466-470.
146. Lomaestro BM, Bailie GR Absorption interactions with fluoroquinolones. Drug Safety 1995, 12:314-333.
147. Anderson LA, Hakojarvi SL, Boudreaux SK Zinc acetate treatment in Wilson's disease. Ann Pharmacother 1998, 32:78-87.
148. Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003, 142:385-390.
149. Santos Silva EE, Sarles J, Buts JP, Sokal EM Successful medical treatment of severely decompensated Wilson disease. J Pediatr 1996, 128:285-287.
150. Durand F, Bernuau J, Giostra E, et al. Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine. Gut 2001, 48:849-852.
151. Stracciari A, Tempestini A, Borghi A, Guarino M. Effect of liver transplantation on neurological manifestations in Wilson disease. Arch Neurol 2000, 57:384-386.
152. Bax RT, Hassler A, Luck W, et al. Cerebral manifestation of Wilson's disease successfully treated with liver transplantation. Neurology 1998, 51:863-865.
153. Kassam N, Witt N, Kneteman N, Bain VG Liver transplantation for neuropsychiatric Wilson disease. Can J Gastroenterol 1998, 12:65-68.
154. Asonuma K, Inomata Y, Kasahara M, et al. Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease. Pediatr Transplant 1999, 3:201-205.
155. Komatsu H, Fujisawa T, Inui A, et al. Hepatic copper concentration in children undergoing living related liver transplantation due to Wilsonian fulminant hepatic failure. Clin Transplant 2002, 16:227-232.
156. Eghtesad B, Nezakatgoo N, Geraci LC, et al. Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg 1999, 5:467-474.
157. Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation 2001, 72:1232-1236.
158. Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilson's disease: long-term results and quality-of-life assessment. Transplantation 2003, 75:1003-1006.
159. Wang XH, Cheng F, Zhang F, Li XC, et al. Copper metabolism after living related liver transplantation for Wilson's disease. World J Gastroenterol 2003, 9:2836-2838.
160. Yoshida Y, Tokusashi Y, Lee GH, Ogawa K Intrahepatic transplantation of normal hepatocytes prevents Wilson's disease in Long-Evans cinnamon rats. Gastroenterology 1996, 111:1654-1660.
161. Malhi H, Irani AN, Volenberg I, et al. Early cell transplantation in LEC rats modeling Wilson's disease eliminates hepatic copper with reversal of liver disease. Gastroenterology 2002, 122:438-447.
162. Allen KJ, Cheah DM, Wright PF, et al. Liver cell transplantation leads to repopulation and functional correction in a mouse model of Wilson's disease. J Gastroenterol Hepatol 2004, 19:1283-1290.
163. Terada K, Nakako T, Yang XL, et al. Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA. J Biol Chem 1998, 273:1815-1820.
164. Ha-Hao D, Merle U, Hofmann C, et al. Chances and shortcomings of adenovirus-mediated ATP7B gene transfer in Wilson disease: proof of principle demonstrated in a pilot study with LEC rats. Z Gastroenterol 2002, 40:209-216.
165. Meng Y, Miyoshi I, Hirabayashi M, et al. Restoration of copper metabolism and rescue of hepatic abnormalities in LEC rats, an animal model of Wilson disease, by expression of human ATP7B gene. Biochim Biophys Acta 2004, 1690:208-219.
166. Shimono N, Ishibashi H, Ikematsu H, et al. Fulminant hepatic failure during perinatal period in a pregnant woman with Wilson's disease. Gastroenterol Jpn 1991, 26:69-73.
167. Walshe JM Pregnancy in Wilson's disease. Q J Med 1977, 46:73-83.
168. Sternlieb I. Wilson's disease and pregnancy. Hepatology 2000, 31:531-532.
169. Sinha S, Taly AB, Prashanth LK, et al. Successful pregnancies and abortions in symptomatic and asymptomatic Wilson's disease. J Neurol Sci 2004, 217:37-40.
170. Mjolnerod IK, Rasmussen K, Dommerud SA, Gjeruldsen ST Congenital connective-tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet 1971, i:673-675.
171. Rosa FW Teratogen update: penicillamine. Teratology 1986, 33:127-131.
172. Pinter R, Hogge WA, McPherson E Infant with severe penicillamine embryopathy born to a woman with Wilson disease. Am J Med Genet A 2004, 128:294-298.
173. Lao TT, Chin RK, Cockram CS, Leung NW Pregnancy in a woman with Wilson's disease treated with zinc. Asia Oceania J Obstet Gynaecol 1988, 14:167-169.
174. Brewer GJ, Johnson VD, Dick RD, et al. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology 2000, 31:364-370.
175. Walshe JM The management of pregnancy in Wilson's disease treated with trientine. Q J Med 1986, 58:81-87.
176. Devesa R, Alvarez A, de las Heras G, Ramon de Miguel J. Wilson's disease treated with trientine during pregnancy. J Pediatr Gastroenterol Nutr 1995, 20:102-103.
177. Berghella V, Steele D, Spector T, et al. Successful pregnancy in a neurologically impaired woman with Wilson's disease. Am J Obstet Gynecol 1997, 176:712-714.
178. Schagen van Leeuwen JH, Christiaens GC, Hoogenraad TU Recurrent abortion and the diagnosis of Wilson disease. Obstet Gynecol 1991, 78:547-549.
179. Oga M, Matsui N, Anai T, et al. Copper disposition of the fetus and placenta in a patient with untreated Wilson's disease. Am J Obstet Gynecol 1993, 169:196-198.
180. Hardman B, Manuelpillai U, Wallace EM, et al. Expression and localization of Menkes and Wilson copper transporting ATPases in human placenta. Placenta 2004, 25:512-517.
181. Roche-Sicot J, Benhamou JP Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease. Ann Intern Med 1977, 86:301-303.
182. McCullough AJ, Fleming CR, Thistle JL, et al. Diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology 1983, 84:161-167.
183. Kalach N, Seidman EG, Morin C, et al. Acute liver failure from Wilson's disease in a five year-old child. Can J Gastroenterol 1993, 7:610-612.
184. Shaver WA, Bhatt H, Combes B Low serum alkaline phosphatase activity in Wilson's disease. Hepatology 1986, 6:859-863.
185. Willson RA, Clayson KJ, Leon S Unmeasurable serum alkaline phosphatase activity in Wilson's disease associated with fulminant hepatic failure and hemolysis. Hepatology 1987, 7:613-615.
186. Hoshino T, Kumasaka K, Kawano K, et al. Low serum alkaline phosphatase activity associated with severe Wilson's disease Is the breakdown of alkaline phosphatase molecules caused by reactive oxygen species?. Clin Chim Acta 1995, 238:91-100.
187. Berman DH, Leventhal RI, Gavaler JS, et al. Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. Gastroenterology 1991, 100:1129-1134.
188. Sallie R, Katsiyiannakis L, Baldwin D, et al. Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure. Hepatology 1992, 16:1206-1211.
189. Tissieres P, Chevret L, Debray D, Devictor D. Fulminant Wilson's disease in children: appraisal of a critical diagnosis. Pediatr Crit Care Med 2003, 4:338-343.
190. Nazer H, Ede RJ, Mowat AP, Williams R Wilson's disease: clinical presentation and use of prognostic index. Gut 1986, 27:1377-1381.
191. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005, 11:441-448.
192. Sallie R, Chiyende J, Tan KC, et al. Fulminant hepatic failure resulting from coexistent Wilson's disease and hepatitis E. Gut 1994, 35:849-853.
193. Lembowicz K, Kryczka W, Walewska-Zielecka B, Kubicka J. Wilson's disease coexisting with viral hepatitis type C: a case report with histological and ultrastructural studies of the liver. Ultrastruct Pathol 1999, 23:39-44.
194. Davies SE, Williams R, Portmann B Hepatic morphology and histochemistry of Wilson's disease presenting as fulminant hepatic failure: a study of 11 cases. Histopathology 1989, 15:385-394.
195. Strand S, Hofmann WJ, Grambihler A, et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 1998, 4:588-593.
196. Valbonesi M, Valente U, Andorno E, et al. Role of intensive PEX in a patient with fulminant hepatic failure due to Wilson's disease (WD) in preparation for orthotopic liver transplantation (OLT). Int J Artif Organs 2003, 26:965-966.
197. Rakela J, Kurtz SB, McCarthy JT, et al. Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantation. Gastroenterology 1986, 90:2004-2007.
198. Nagata Y, Uto H, Hasuike S, et al. Bridging use of plasma exchange and continuous hemodiafiltration before living donor liver transplantation in fulminant Wilson's disease. Intern Med 2003, 42:967-970.
199. Kreymann B, Seige M, Schweigart U, et al. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol 1999, 31:1080-1085.
200. Manz T, Ochs A, Bisse E, et al. Liver support - a task for nephrologists? Extracorporeal treatment of a patient with fulminant Wilson crisis. Blood Purif 2003, 21:232-236.